London, Infront (INFRT) announced today that the Infront Professional Terminal has been chosen by the University College Birmingham in England for their new trading suite. It is the first university trading suite to be powered by Infront, with 21 Infront Professional Terminals in place, offering unique benefits for students.
Infront and vwd have joined forces. Working together under the Infront brand, we offer market data, portfolio management and regulatory solutions that cover your entire workflow. In in this edition of our newsletter you will find all the latest information on our extended product range, which you will benefit from as a result of our merger.
On Thursday, 27 February 2020 from 10:30 to 14:30, interested professionals have the opportunity to introduce themselves personally to us at the Career Information Centre - Main-BiZ. Please bring your complete, meaningful application documents with you.
You can get an overview of our open positions here.
The EMEA Trading Conferenceis Europe’s largest one-day electronic trading event. The event will cover the most pressing issues facing the institutional trading community and provide a neutral platform for buy-side, sell-side, exchanges, vendors and regulators to share their ideas on how the community can continue to collaborate. Designed to appeal to all asset classes, the agenda will maintain a great balance of topics across multiple asset classes.
The BVI Fund Operations Conference will inform you about the trends in the securities and fund industry on 31 March 2020 in Cape Europe - with more than 40 presentations in parallel tracks.
In addition, you can expect interesting presentations on topics such as sustainability, digitization, information security, financial market data, trading, regulatory and investor reporting, real estate management and custodian issues.
Further information about the event can be found here...
When great people and great companies come together, amazing potential can be realized. Join the Tech Job Fair! Update your resume, and get ready for an interview with us. Here you'll find our current vacancies.
23.04.2020, 18.00 - 21.00
Software Improvement Group
Fred. Roeskestraat 115
Amsterdam, 1076 EE Netherlands
Every year more than 11,000 students use konaktiva to get closer to an internship, a working student position and even their dream job.
Come by and get to know us! You are also welcome to make an appointment with us in advance. Please contact Stefanie Blasi by mail.
12. May 2020, 09:30 - 16:30 o'clock
darmstadtium (Science and Congress Centre), Schloßgraben 1, 64283 Darmstadt, Germany
Students of all disciplines and universities
Visiting the fair is free of charge and does not require registration. The konaktiva is organised by a team of volunteer students.
Motivated graduates and students of all disciplines from universities and universities of applied sciences from all over southwest Germany have the opportunity to get to know what we have to offer and make their first contacts at the meeting point company contact fair in Kaiserslautern.
You will find us from 10.00 to 16.00 in building 42 of the TU Kaiserslautern. You are also welcome to arrange an appointment with us in advance. Please send an e-mail to Sandra Schintu.
We will again be represented at the DKF this year and look forward to your visit to our stand.
Further information will be available here soon or on the official DKF 2020 website.
24.01.2020 BUSINESS WIRE: Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
Ipsen has decided to pause dosing in the palovarotene trials
Based on encouraging therapeutic activity signals observed in preliminary post-hoc analyses and recommendations from the Independent Data Monitoring Committee, Ipsen to conduct further assessment of the complete data set and work with the regulatory authorities to determine the path forward
PARIS --(BUSINESS WIRE)-- 24.01.2020 --
Ipsen (Euronext: IPN; ADR: IPSEY) today announced the decision to pause dosing patients in the global Phase III (PVO-1A-301) study designed to evaluate the efficacy and safety of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), as well as the ongoing Phase II (PVO-1A-202/204) extension studies. In both the Phase III and Phase II extension studies, palovarotene is dosed both chronically (daily) and episodically (during flare-ups). The decision to pause dosing patients in the trial is based on results of a futility analysis reviewed by the Independent Data Monitoring Committee (IDMC) as part of the prespecified interim analysis. The results of a futility analysis indicated that the Phase III FOP trial was unlikely to meet its primary efficacy endpoint (annualized change in new HO volume as compared with Natural History Studyi) upon completion.
Despite the results of the prespecified interim analysis, signals of encouraging therapeutic activity were observed in preliminary post-hoc analyses of the Phase III trial and shared with and acknowledged by the IDMC which is recommending not to discontinue the study. In its recommendations, the IDMC notes highly disparate results precluding a confident conclusion about futility. The IDMC also points out that the protocol-prespecified model may have negatively affected the efficacy analysis and shifted the statistical conclusion from significant therapeutic benefit to showing futility of the treatment. The FDA partial clinical hold for the pediatric population under the age of 14 for FOP and multiple osteochondromas (MO) issued on 4 December 2019, remains in effect.
Ipsen will pause dosing patients in the trials and conduct further assessment of the complete data set. Based on the IDMC’s observations and recommendations, Ipsen will discuss these findings with regulatory authorities to determine the path forward for the palovarotene program in FOP. Ipsen will collaborate and consult with the patients, investigators, ethics committees and regulatory authorities to define next steps for the program, in the best interests of patients, whilst ensuring consent of all parties involved.
“While the study has met prespecified statistical futility, we are encouraged by the results observed in the preliminary post-hoc analyses and look forward to discussing these with regulators as quickly as possible to determine the next steps for the palovarotene program,” said Aymeric Le Chatelier, Chief Executive Officer at Ipsen. “We gratefully acknowledge the ongoing support and trust from patients, their families and the healthcare professionals involved in these trials. We are deeply committed to drug development in the area of rare and ultra-rare diseases where there are multiple high unmet medical needs and often a limited understanding of the disease itself.”
Ipsen is currently assessing the financial implications of these developments, including the financial outlook for 2022, and will present in February updated views together with Full Year 2019 results.
Palovarotene is a RARγ agonist being developed as a potential treatment for patients with ultra-rare and debilitating bone diseases, including fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), as well as other conditions including dry eye disease. Palovarotene, which had rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder, was acquired by Ipsen through the acquisition in April 2019 of Clementia Pharmaceuticals.
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas: Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.2 billion in 2018, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.
Ipsen—Cautionary Note Regarding Forward-Looking Statements
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2018 Registration Document available on its website (www.ipsen.com).
i *Prospective Natural History Study (NHS), the first multi-center, non-interventional, two-part longitudinal study designed to measure disease progression over three years in patients with FOP.
For further information:
Christian Marcoux, M.Sc.
Senior Vice President, Global Communications
+33 (0)1 58 33 67 94
Director, Global Communications
+1 (857) 998-7036
Vice President, Investor Relations
+44 (0) 1753 627721
Investor Relations Manager
+33 (0)1 58 33 51 04
19.02.2020 Mynewsdesk: CreaLog auf der CCW 2020: Wie digital ist Ihre Kundenkommunikation? KI-basierte Lösungen im Fokus
?Berlin/München, im Februar 2020 - Evolutionäre Ideen, neue Plattform-Technologien und intelligente, KI-basierte Lösungen prägen das Zeitalter der digitalen Transformation. Wie das in der Praxis aussieht, präsentieren die Experten von CreaLog vom 2. bis 4. März auf der ...
19.02.2020 Mynewsdesk: Physiotherapeuten integrieren neue Arthrose-Behandlung - Neue FPZ HüfteKnieTherapie ohne Lizenzkosten
Die Gesundheitsbranche ist um eine erfolgversprechende und attraktive Behandlungsoption reicher: FPZ hat damit begonnen, seine neue FPZ HüfteKnieTherapie auszurollen. Diese können Physiotherapiepraxen und -zentren ab sofort ohne großen logistischen sowie finanziellen Aufwand in ihr ...
18.02.2020 Mynewsdesk: Zukunftslösung für Einzelhandel: NewStore & Decathlon erhalten 'EHI reta' Auszeichnungen für Omnichannel Excellence
- NewStore erhält „Top Supplier Retail Award 2020“- Decathlon als beste Omnichannel-Lösung für die Nutzung der NewStore-Plattform ausgezeichnetBOSTON & DÜSSELDORF - 18. Februar 2020 - NewStore, das erste Unternehmen, das Omnichannel-as-a-Service anbietet, ...
18.02.2020 Mynewsdesk: Cyber-Versicherung: SIGNAL IDUNA kooperiert mit ROLAND Schutzbrief
Sicher zuhause – und im Netz- SIGNAL IDUNA bietet ab sofort Internetschutz als Zusatzbaustein bei Haftpflicht- und Hausratversicherungen an.- Die Bausteine „Privat-Haftpflicht Cyber“ und „Hausrat Cyber“ beinhalten Leistungen des ROLAND-Schutzbriefs ...
13.02.2020 Mynewsdesk: Life Science Start-up BIOMES erhält zwei Millionen Euro von yabeo
BIOMES: https://biomes.world/ startet mit einer erfolgreichen Pre-Series A-Finanzierungsrunde ins Jahr 2020. Das Life Science Unternehmen erhält zwei Millionen Euro vom Frühphasen-Finanzierer yabeo: http://yabeo.de/en/home/ aus München. BIOMES untersucht mithilfe modernster ...
11.02.2020 Mynewsdesk: Digitale Transformation im Handel: Burton Snowboards setzt auf Omnichannel-Plattform von NewStore
- Das weltweit führende Snowboard-Unternehmen wird in Zukunft seinen Verkauf über Smartphones abwickeln- Die innovative Omnichannel-Lösung beinhaltet Warenwirtschaft, „Endless Aisle“, „Fulfillment“ und mobiles BezahlenNewStore: http://www.newstore.com/, ...
25.02.2020 GlobeNewswire: Zadara bietet Unterstützung für unveränderlichen Objektspeicher von Veeam
Zadara bietet Unterstützung für unveränderlichen Objektspeicher von Veeam Die neue Erweiterung der branchenführenden STaaS-Plattform bietet ein neues Niveau an Datensicherhei IRVINE, Kalifornien, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Zadara Storage Inc. , ein wegweisender Marktführer im Bereich Storage as a Service für Unternehmen...
25.02.2020 GlobeNewswire: LeddarTech stellt am 2.–3. März 2020 auf der TECH.AD Berlin aus und informiert über die kritische Bedeutung der LiDAR-Technologie für Fahrassistenzsysteme und autonomes Fahren
LeddarTech stellt am 2.–3. März 2020 auf der TECH.AD Berlin aus und informiert über die kritische Bedeutung der LiDAR-Technologie für Fahrassistenzsysteme und autonomes Fahren QUEBEC CITY, Feb. 25, 2020 (GLOBE NEWSWIRE) -- LeddarTech ® , ein Branchenführer auf dem Gebiet der LiDAR-Technologie und Anbieter der vielseitigsten und...
25.02.2020 GlobeNewswire: Pacific Rim in Veröffentlichung über Indonesiens Strategie zur Steigerung der Nickelproduktion vorgestellt
Pacific Rim in Veröffentlichung über Indonesiens Strategie zur Steigerung der Nickelproduktion vorgestellt NEW YORK, Feb. 25, 2020 (GLOBE NEWSWIRE) -- über NetworkWire -- Die Pacific Rim Cobalt Corp. (CSE:BOLT) (OTCQB:PCRCF) (XFRA:NXFE) freut sich über Erwähnung in Leitartikel von NetworkNewsWire („NNW“), einer von mehr als 40...
25.02.2020 GlobeNewswire: Feintool erschliesst asiatischen Markt von e-Motor-Komponenten
Feintool erschliesst asiatischen Markt von e-Motor-Komponenten Expansion in China: Neben Deutschland wird das Technologieunternehmen in 2020 auch im Zukunftsmarkt China Elektroblech-Komponenten für e-Motoren anbieten. Am bestehenden Standort Taicang, nahe Shanghai, werden erste Produktionslinien aufgebaut. Der chinesische...
25.02.2020 GlobeNewswire: SIKA WIRD MITGLIED DER INITIATIVE „TOGETHER FOR SUSTAINABILITY“
SIKA WIRD MITGLIED DER INITIATIVE „TOGETHER FOR SUSTAINABILITY“ SIKA WIRD MITGLIED DER INITIATIVE „TOGETHER FOR SUSTAINABILITY“ Sika freut sich als neues Mitglied der Initiative „Together for Sustainability“ (TfS) beizutreten. Die 2011 gegründete Organisation will die Nachhaltigkeitspraxis innerhalb der Supply Chain von...
25.02.2020 GlobeNewswire: Mocana führt TrustCenter 2020 ein
Mocana führt TrustCenter 2020 ein Cyber Protection as a Service für vertrauenswürdige Systeme Sunnyvale, Kalifornien, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Mocana Corporation , der führende Anbieter von OT-Sicherheitslösungen für geschäftskritische Anwendungen in industriellen Kontrollsystemen (ICS) und im Internet der Dinge...
Subscribe to our free newsletter and you will receive the latest information about our products and solutions.